Abstracts tagged "immunology"

Abstract Number: 2418 • ACR Convergence 2025
ORF1p Expression Correlates with STING Activation and IFN Signatures in SLE Nonlesional Skin
Mehrnaz Gharaee-Kermani¹, Svenja Henning², John LaCava³, Tomas Mustelin⁴ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Groningen, Groningen, Groningen, Netherlands, ³Rockefeller University, New York City, NY, NJ, ⁴University of Washington, Seattle, WA
Background/Purpose: Type I interferons (IFNs) are elevated in the skin and blood of patients with systemic (SLE) and cutaneous (CLE) lupus erythematosus. Upregulation of type…
Abstract Number: 1845 • ACR Convergence 2025
Immune Cell Profiles and Transcriptomic Signatures of Atherosclerosis in Systemic Lupus Erythemathosus
Rodolfo Martinez-Canales¹, Andres M. Ortiz-Rios², Braulio R. Avalos-Garcia², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Noe Macias-Segura¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) significantly increases the risk of premature atherosclerosis, contributing to long-term morbidity and mortality. Traditional cardiovascular risk factors do not fully…
Abstract Number: 1695 • ACR Convergence 2025
The B Cell Compartment Exhibits a Pro-Inflammatory Skewing During Progression to Rheumatoid Arthritis
Ziyuan He¹, Marla Glass¹, Mark Gillespie¹, Elisabeth Dornisch¹, Pravina Venkatesan², Troy Torgerson³, Kevin Deane⁴, Gary Firestein⁵, Adam Savage¹, Xiaojun Li¹, V. Michael Holers⁶, Fan Zhang⁷, David Boyle⁸, Christy Bennett¹, Kristine Kuhn⁹, Kristen Demoruelle¹⁰, Peter Skene¹¹ and Ananda Goldrath¹¹, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Insitute, Seattle, WA, ³Allen Institute for Immunology, Enumclaw, WA, ⁴University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁵University of California, San Diego, San Diego, CA, ⁶University of Colorado, Denver, CO, ⁷The University of Colorado, Aurora, CO, ⁸UCSD, La Jolla, CA, ⁹²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO, ¹⁰University of Colorado Anschutz Medical Campus, Golden, CO, ¹¹Allen Institute for Immunology, Seattle
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and bone destruction. RA is preceded by a subclinical phase defined by elevated…
Abstract Number: 1113 • ACR Convergence 2025
Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort
Qi Wang¹, Zhiting Tang² and Lei Deng³, ¹Metrohealth System/Case Western Reserve University, Cleveland, OH, ²Unity Hospital, Rochester, NY, ³Fred Hutchinson Cancer Center, Seattle, WA
Background/Purpose: Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare but life-threatening immune-related adverse event (irAE), with a mortality rate of 30–50%. Most available evidence comes…
Abstract Number: 0943 • ACR Convergence 2025
Type I and Type II IFNs have both independent and overlapping effects on SLE disease severity
Haylee Cosgrove¹, Xiaoyan Gong¹, Aidan Matunis¹ and Jeremy Tilstra², ¹University of Pittsburgh, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The pathogenesis of systemic lupus erythematosus (SLE) is thought to be strongly influenced by the interferon (IFN) signaling pathway, particularly type I IFNs (IFNα/β).…
Abstract Number: 0866 • ACR Convergence 2025
Immunoglobulin from sera of patients with myositis can passively enter cultured human endothelial cells
Travis Kinder¹, maria Casal-Dominguez¹, Iago Pinal Fernandez², Andrew Mammen³ and Sandra Ogbonnaya-Whittlesey⁴, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³NIH, Bethesda, MD, ⁴NIH/NIAMS, Bethesda, MD
Background/Purpose: Most patients with inflammatory myopathies have autoantibodies to intracellular proteins. We previously showed that immunoglobulin colocalizes with its cognate autoantigen in muscle biopsies from…
Abstract Number: 0059 • ACR Convergence 2025
Formyl Peptide Receptor 1 (FPR1) Influences Arthritis Severity in a Sex- and Compartment-Specific Manner
Ryan D. Stultz¹, Payton Hermanson², Noelle Mullin³, Simeon Ramsey³ and Christian Lood², ¹University of Washington, Division of Rheumatology, Seattle, WA, ²University of Washington, Seattle, WA, ³Pfizer Inc., Cambridge, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that disproportionately affects females over males (3:1). Although sex-based immune differences have been documented, particularly…
Abstract Number: 2417 • ACR Convergence 2025
Anti-dense fine speckled 70 antibodies in undefined disease, systemic autoimmune rheumatic diseases and controls
Rammohan Mylavarapu¹, Meghna Gavali², Bansi Kashyap Parijeya³, Kaushik Puranam⁴ and Liza rajasekhar⁵, ¹NIZAMS INSTITUTE OF MEDICAL SCIENCES, Hyderabad, Telangana, India, ²nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, ³Synergy superspeciality hospital, Rajkot, Gujarat, India, ⁴Nizams Institute Of Medical Sciences , Hyderabad, hyderabad, Telangana, India, ⁵Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Systemic autoimmune rheumatic diseases (SARD) are a heterogeneous group of disorders marked by the presence of antinuclear antibodies (ANA), commonly detected by HEp-2 cell-based…
Abstract Number: 1829 • ACR Convergence 2025
Multiomic Investigation of Juvenile Idiopathic Arthritis Synovium Reveals Immune Cell Heterogeneity
Abigail Thielbar¹, Tracy Ting², Lexi Auld³, Kelly Rogers⁴, Megan Quinlan-Waters⁵, Sheila Angeles-Han⁴, Ekemini Ogbu², Daniel Lovell², Jennifer Huggins⁶, Grant Schulert², Patricia Vega-Fernandez² and Yuriy Baglaenko⁴, ¹Cincinnati Children's Hospital, Cincinnati, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, CCHMC, ⁶Cincinnati Children's Medical Center, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease of childhood, affecting 1:1,000 children worldwide. The hallmark of JIA is immune-mediated…
Abstract Number: 1653 • ACR Convergence 2025
Gut-joint lymphocyte trafficking functions to regulate systemic immunity
Sarah Danielson¹, Sucai Liu² and Kristine Kuhn³, ¹University of Colorado Anschutz Medical Campus, Aurora, ²University of Colorado School of Medicine, Aurora, CO, ³²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO
Background/Purpose: The gut-joint and mucosal origins hypotheses postulate that immune alterations in mucosal sites may precede and impact the development of rheumatoid arthritis and spondyloarthritis.…
Abstract Number: 1109 • ACR Convergence 2025
Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Laurianne Simard¹, Nathalie Amiable², Ines Colmegna³, Anne-Sophie Julien⁴, Sonia Léger-Thériault⁵, Alexandra Godbout⁴, Lison Fournier⁶, Giuliana Alfonso⁵, Josiane Bourre-Tessier⁷, Marie Hudson⁸, Nicolas Richard⁹, Jean-Paul Makhzoum¹⁰, Arielle Mendel¹¹, Sasha Bernatsky¹², Marc Dionne⁶, Michael Libman⁵, Gaston De Serres⁶ and Paul Fortin¹³, ¹Universite Laval, Quebec, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Centre de recherche du CHU de Québec – Université Laval, Quebec, QC, Canada, ⁵MUHC, Montreal, Canada, ⁶Centre de recherche du CHU de Québec – Université Laval, Quebec, Canada, ⁷Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ⁸McGill University, Montréal, QC, Canada, ⁹Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁰Universite de Montreal, Montreal, Canada, ¹¹McGill University Health Centre, Montréal, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) treated with B-cell-depleting therapies such as rituximab (RTX) have impaired humoral immune responses, increasing their susceptibility to…
Abstract Number: 0923 • ACR Convergence 2025
Influenza Virus Infection Alters the MHC Class II Self-Immunopeptidome to Present Lupus-Associated Autoantigens
Julia Rood¹, Stephanie Suh Kyung Yoon², Mary Heard¹, Michael Hogan², Nicola Ternette³, Edward Behrens⁴ and Laurence Eisenlohr¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Dundee, Dundee, Scotland, United Kingdom, ⁴CHOP, West Chester, PA
Background/Purpose: Viral infections and major histocompatibility complex class II (MHC II) are both implicated in the genesis of systemic lupus erythematosus (SLE), but a mechanistic…
Abstract Number: 0864 • ACR Convergence 2025
Immunophenotyping Reveals Upregulated IL-9R on Circulating T and B Cells in Dermatomyositis
Danica Lee¹, Daniel Reay², Timothy Oriss², Didem Saygin³, Dana Ascherman⁴ and Daniella Schwartz⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³Rush University Medical Center, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM), or myositis, comprise a group of autoimmune diseases with significant morbidity, yet the pathogenesis of myositis remains incompletely understood. In…
Abstract Number: 0055 • ACR Convergence 2025
TCR Signaling Thresholds Govern Anergy and Tolerance in ZAP70 Hypomorphic Models of Autoimmune Arthritis
Yuka Nakao, Astha Patel, Letitia Yang, Steven yu, Arthur Weiss and Judith Ashouri, University of California, San Francisco, San Francisco, CA
Background/Purpose: T cell receptor (TCR) signaling strength is a key determinant of immune tolerance and autoimmunity, yet the threshold needed to prevent pathogenic self-reactivity remains…
Abstract Number: 2399 • ACR Convergence 2025
Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine
Gregg Silverman¹, Abhimanyu Amarnani², Zakia Azad² and Brad Rovin³, ¹NYU Grossman School of Medicine, New York, NY, ²New York University Grossman School of Medicine, New York, NY, ³The Ohio State University, Columbus, OH
Background/Purpose: During disease, ~50% of SLE patients develop lupus nephritis (LN), one of the most serious complication. Despite the best therapy, within 15 years, ~20%…

1
2
3
…
33
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].